AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
286.28B
Market cap286.28B
Price-Earnings ratio
27.09
Price-Earnings ratio27.09
Dividend yield
1.73%
Dividend yield1.73%
Average volume
1.81M
Average volume1.81M
High today
$184.56
High today$184.56
Low today
$181.76
Low today$181.76
Open price
$183.44
Open price$183.44
Volume
623.74K
Volume623.74K
52 Week high
$212.71
52 Week high$212.71
52 Week low
$136.16
52 Week low$136.16

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $184.26. The company's market cap stands at 286.28B, with a P/E ratio of 27.09 and a dividend yield of 1.7%.

On 2026-05-18, AstraZeneca(AZN) stock moved within a range of $181.76 to $184.56. With shares now at $184.26, the stock is trading +1.4% above its intraday low and -0.2% below the session's peak.

Trading activity shows a volume of 623.74K, compared to an average daily volume of 1.81M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $136.16.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $136.16.

AZN News

Benzinga 15m
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios

AstraZeneca Secures FDA Approval For Baxfendy In Hypertension The company also announced expanded FDA approvals for Enhertu in HER2-positive early breast cance...

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios
TipRanks 3h
AstraZeneca CEO Pascal Soriot Receives Vesting of Performance Share Award

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 6h
AstraZeneca announces U.S. approval for BAXFENDY in hypertension

AstraZeneca’s (AZN) BAXFENDY has been approved in the US as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination wit...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

TipRanks 6h
Compugen reports Q1 EPS (8c) vs. (8c) last year

Reports Q1 revenue $2.2M vs. $2.3M last year. Compugen (CGEN) expects that its cash and cash-related balances will be sufficient to fund its operating plans int...

TipRanks 8h
‘We Have Been Waiting… for Many Years’: AstraZeneca Stock Drops despite Win for Potential Blockbuster Pill

AstraZeneca’s (AZN) shares edged lower early Monday despite the British pharma giant securing approval for its Baxfendy (baxdrostat) blood pressure pill. The dr...

TipRanks 10h
FDA approvals extend Enhertu into curative-intent HER2-positive early breast cancer

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

The Wall Street Journal 11h
AstraZeneca Gets U.S. Approval for Hypertension Drug

The approval expands AstraZeneca’s cardiovascular, renal and metabolism portfolio. Rachel Wisniewski / Reuters AstraZeneca AZN -0.79 %decrease; red down pointi...

AstraZeneca Gets U.S. Approval for Hypertension Drug
Benzinga 4d
AstraZeneca's Imfinzi Combo Shows Survival Benefit In Pivotal Bladder Cancer Study

The study compared the regimen against standard treatment involving radical cystectomy, with or without approved adjuvant therapy. The European drug giant said...

AstraZeneca's Imfinzi Combo Shows Survival Benefit In Pivotal Bladder Cancer Study
TipRanks 4d
AstraZeneca’s SECURE Study Targets Real-World Tagrisso Persistence in China

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper de...

TipRanks 4d
AstraZeneca Deepens China Lung Cancer Insights With New NSCLC Chart Review

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper de...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.